Can harnessing radio waves boost human longevity?

Radio frequency technology that shows promise in Alzheimer’s treatment is now being explored for its potential in longevity.

Back in 2010, researchers at the University of South Florida’s Alzheimer’s Institute conducted a study exploring the potential negative impact of radio frequency waves on the brain. At the time, the use of cell phones was becoming ubiquitous, and there were concerns that the impact of RF waves could be detrimental to human health.

The scientists exposed transgenic mice with Alzheimer’s to RF waves, expecting to find that cognitive decline was accelerated, but were surprised to find that the opposite happened – the mice were protected from further deterioration and even had their cognitive impairment reversed if they were in older age. The subsequent paper in the Journal of Alzheimer’s Disease created headlines around the world.

The researchers behind that study went on to develop an approach dubbed Transcranial Radiofrequency Wave Treatment (TRFT) and created a head-worn product called the MemorEM, which received Breakthrough Device designation from the US FDA as a potential treatment for Alzheimer’s in humans. Today, the lead scientist behind the technology, former University of South Florida Research professor Gary Arendash, has embarked on a new venture that aims to demonstrate TRFT can also extend human healthspan and longevity.

My take on this: Having demonstrated the ability of TRFT to stop and reverse cognitive impairment in Alzheimer’s patients in several studies, Dr Arendash recently founded a new enterprise called RF Longevity to expand clinical studies into increasing healthy longevity in humans. The new enterprise’s focus on longevity is driven by recent study data, which indicated that the treatment has a “rebalancing” effect on the immune system, potentially helping reduce the chronic inflammation that is associated with many age-related diseases. To learn more, we caught up with Arendash, founder of RF Longevity.

Arendash begins by revealing his personal “litmus test” for determining if a therapeutic is a serious candidate for extending human longevity.

“First, I think it should have completed at least one clinical trial involving a major disease of aging,” he says. “Second, it should show clear evidence of clinical benefit and, finally, it should have no significant side effects. I believe TRFT meets all these criteria and thus should be considered a gerotherapeutic front-runner for extending human longevity.”

Find out why results in humans are vital, how TRFT is rejuvenating the immune system and how Alzheimer's reversal is being demonstrated straight from Dr Gary Arendash HERE .

Thanks for reading! If you’ve enjoyed this article, it would mean a lot to me if you could subscribe and share it on LinkedIn!